ABSTRACT
Menopausal hormone therapy (HT) may influence colorectal cancer risk. A total of 136,275 postmenopausal women from the European Prospective Investigation into Cancer and Nutrition were followed for an average of 9 years, during which time 1,186 colorectal cancers were diagnosed. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models stratified by center and age, and adjusted for body mass index, smoking, diabetes, physical activity and alcohol consumption. Compared to never use of HT at study enrollment, current use of estrogen-only (HR, 1.02; 95% CI, 0.79-1.31) or estrogen plus progestin (HR, 0.94; 95% CI, 0.77-1.14) was not significantly associated with the risk of colorectal cancer, and these associations did not vary by recency, duration, route of administration, regimen or specific constituent of HT. Our results show no significant association of estrogen-only or estrogen plus progestin therapy with colorectal cancer risk.
Subject(s)
Colorectal Neoplasms/epidemiology , Hormone Replacement Therapy , Postmenopause , Cohort Studies , Female , Humans , Middle Aged , Nutritional Sciences , Prognosis , Proportional Hazards Models , Prospective Studies , Risk Factors , Surveys and Questionnaires , White PeopleABSTRACT
Colorectal cancer (CRC) is the third most common malignant tumor and the fourth leading cause of cancer death worldwide. The crucial role of fatty acids for a number of important biological processes suggests a more in-depth analysis of inter-individual differences in fatty acid metabolizing genes as contributing factor to colon carcinogenesis. We examined the association between genetic variability in 43 fatty acid metabolism-related genes and colorectal risk in 1225 CRC cases and 2032 controls participating in the European Prospective Investigation into Cancer and Nutrition study. Three hundred and ninety two single-nucleotide polymorphisms were selected using pairwise tagging with an r(2) cutoff of 0.8 and a minor allele frequency of >5%. Conditional logistic regression models were used to estimate odds ratios and corresponding 95% confidence intervals. Haplotype analysis was performed using a generalized linear model framework. On the genotype level, hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD), phospholipase A2 group VI (PLA2G6) and transient receptor potential vanilloid 3 were associated with higher risk for CRC, whereas prostaglandin E receptor 2 (PTGER2) was associated with lower CRC risk. A significant inverse association (P < 0.006) was found for PTGER2 GGG haplotype, whereas HPGD AGGAG and PLA2G3 CT haplotypes were significantly (P < 0.001 and P = 0.003, respectively) associated with higher risk of CRC. Based on these data, we present for the first time the association of HPGD variants with CRC risk. Our results support the key role of prostanoid signaling in colon carcinogenesis and suggest a relevance of genetic variation in fatty acid metabolism-related genes and CRC risk.
Subject(s)
Adenocarcinoma/genetics , Colorectal Neoplasms/genetics , Fatty Acids/metabolism , Genetic Association Studies , Polymorphism, Single Nucleotide , Adenocarcinoma/epidemiology , Adenocarcinoma/metabolism , Alleles , Case-Control Studies , Cohort Studies , Colorectal Neoplasms/epidemiology , Colorectal Neoplasms/metabolism , Europe/epidemiology , Female , Genotype , Group III Phospholipases A2/genetics , Group VI Phospholipases A2/genetics , Haplotypes , Humans , Hydroxyprostaglandin Dehydrogenases/genetics , Male , Neoplasm Proteins/genetics , Receptors, Prostaglandin E/genetics , Receptors, Prostaglandin E, EP2 Subtype , Smoking/epidemiology , TRPV Cation Channels/geneticsABSTRACT
Previous case-control studies have suggested that a high intake of animal foods and its associated nutrients are associated with an increased risk of renal cell carcinoma, although data from prospective studies are limited. We report here on the relationship between macronutrient intake and renal cell carcinoma incidence among 435,293 participants enrolled in the European Prospective Investigation into Cancer and Nutrition. Cox proportional hazard models were used to examine the association of dietary intake of fat, protein, carbohydrate, fiber and cholesterol and risk of renal cell carcinoma adjusted for age, sex, center, height, body mass index, physical activity, education, smoking, menopausal status, alcohol and energy intake. During an average 8.8 years of follow-up, 507 renal cell carcinoma cases occurred. Risk of renal cell carcinoma was not associated with macronutrient intake, including nutrients derived from animal sources. Our results indicate that macronutrient intake is not associated with risk of renal cell carcinoma in this cohort of European men and women.
Subject(s)
Carcinoma, Renal Cell/epidemiology , Kidney Neoplasms/epidemiology , Meat/adverse effects , Adult , Aged , Body Mass Index , Carcinoma, Renal Cell/etiology , Cohort Studies , Confounding Factors, Epidemiologic , Dietary Fats , Feeding Behavior , Female , Follow-Up Studies , Humans , Kidney Neoplasms/etiology , Male , Middle Aged , Prospective Studies , Risk Assessment , Risk Factors , Surveys and QuestionnairesABSTRACT
OBJECTIVE: We previously showed that Adamantiades-Behçet's disease (A-BD) is associated with a lower incidence of malignancy compared with the general population. Transforming growth factor-beta (TGF-beta) has been shown to play a role in cartilage regeneration and is increased in patients with A-BD. We also found 2 functional polymorphisms of the TGF-beta pathway, TGFBR1*6A and TGFB1*CC, that are associated with risk of malignancy. We tested whether incidence of these polymorphisms would differ in patients with A-BD compared with healthy controls of similar age and geographic location. METHODS: We performed a case-control study including 139 cases and 128 controls from Greece. Cases and controls were genotyped for TGFBR1*6A and TGFB1*CC. RESULTS: We found that cases had lower incidence of TGFBR1*6A compared with controls (11.3% vs 13.3%, respectively). Also, the incidence of TGFB1*CC was lower in cases than controls (24.6% vs 27.0%, respectively). These differences were not statistically significant. CONCLUSION: Although there is a suggestion that the lower incidence of TGFBR1*6A in A-BD patients may play a protective role against development of malignancy, larger studies would be needed to fully evaluate the role of TGF-beta and its polymorphisms in A-BD.
Subject(s)
Behcet Syndrome/genetics , Genetic Predisposition to Disease/genetics , Protein Serine-Threonine Kinases/genetics , Receptors, Transforming Growth Factor beta/genetics , Transforming Growth Factor beta1/genetics , Adolescent , Adult , Aged , Case-Control Studies , Female , Humans , Male , Middle Aged , Polymorphism, Single Nucleotide/genetics , Receptor, Transforming Growth Factor-beta Type I , Young AdultABSTRACT
Activation of ras genes and human papilloma virus (HPV) infection have been extensively described in cervical carcinomas while information concerning their implication in premalignant lesions of the cervix is limited. We investigated the incidence of K-ras codon 12 point mutations and HPV infection in cases of cervicitis and cervical intraepithelial neoplasias (CIN). Forty-seven cases of women with cervicitis or CIN were examined for the presence of K-ras mutations and HPV infection using PCR-RFLP methodology. Furthermore, HPV typing was carried out in HPV positive samples by multiplex PCR. K-ras mutations were detected in 7/47 cases (15%) while HPV genome was found in 17/47 cases (36%). HPV typing revealed HPV-18 at a higher rate than HPV-16 (71% vs 29%). No statistically significant association was observed between the presence of K-ras mutations, HPV infection and clinical parameters or smoking-alcohol habits. Our results suggest that mutational activation of K-ras gene is implicated in the development of premalignant cervical lesions and HPV infection may be an important step in the development of premalignant cervical lesions.